A synthetic 39-amino-acid research peptide in the incretin family — one of the newer multi-target compounds. Supplied as a single-lot reference material.
Vial size
$57.60
10 mg / vial · $5.76 / mg
Quantity
Add 1 more for 3% off
Bundle & save
1 vial
$57.60
each
2 vials
$55.87
3% off
3+ vials
$54.72
5% off
Per-vial price shown. The discount applies automatically at checkout.
Purchase options
Verification
Every batch is identified by a lot number, and its third-party certificate is listed here by lot. Measured values are shown only when they are real and independently verifiable.
Third-party testing in progress
We are currently having this product independently tested by a third-party laboratory. Its certificate of analysis will be published here as soon as the results are available — please check back soon. For laboratory research use only.
Retatrutide is a synthetic research peptide of thirty-nine amino acids from the incretin family — one of the newer multi-target compounds drawing steady interest in laboratory research.
Vestrand carries it as one reference lot at a time, prepared for independent third-party testing, and the certificate of analysis for each lot goes up on its verification page as soon as the work is finalized.
What makes it notable is its class rather than any single figure: it is a tri-agonist, defined by acting on three separate receptor targets at once, which places it among the most-watched reference compounds in the incretin collection. Purity is stated as one specification and confirmed for each lot.
For laboratory research use only. Not for human or veterinary use.
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors — a tri-agonist incretin analogue. It is studied within incretin and metabolic-pathway research as one of the most-referenced multi-target compounds in the class.
Independent peer-reviewed literature that references Retatrutide.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM et al.
N Engl J Med2023
View source for Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (opens in a new tab)Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J et al.
Lancet2023
View source for Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (opens in a new tab)The power of three: Retatrutide's role in modern obesity and diabetes therapy
Abdul-Rahman T et al.
Eur J Pharmacol2024
View source for The power of three: Retatrutide's role in modern obesity and diabetes therapy (opens in a new tab)Retatrutide - A Game Changer in Obesity Pharmacotherapy
Katsi V et al.
Biomolecules2025
View source for Retatrutide - A Game Changer in Obesity Pharmacotherapy (opens in a new tab)Citations are provided for educational and scientific reference only. They describe independent published research and are not product claims — they do not represent the performance, purity, or intended use of any material offered for sale.
General handling guidance for laboratory research materials — always defer to the product label and the lot certificate of analysis.
Research use only
For laboratory research use only. Not for human or veterinary use.
No reviews yet
Reviews are published only from verified purchases, so none appear until orders ship.
Peptide
A short synthetic peptide corresponding to a tail-end fragment of human growth hormone, with one extra building block added at the front.
Peptide
A synthetic peptide of fifteen building blocks (a pentadecapeptide), based on a partial sequence of a protein first identified in gastric juice.
Peptide blend
A blend of two peptides — BPC-157 and TB-500 — supplied together. A mixture, not a single substance, with no identity of its own.
Peptide
A growth-hormone-releasing factor analogue of twenty-nine building blocks, also known as Modified GRF (1-29). Easily confused with the closely related sermorelin.